PHK
SLNO

Point72 Hong Kong’s Soleno Therapeutics SLNO Stock Holding History

Point72 Hong Kong’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-24
Closed -$1K – 2020
2020
Q3 		$1K Buy
24
+4
+20% +$117 ﹤0.01% 1143
2020
Q2 		$1K Buy
+20
New +$867 ﹤0.01% 1098

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Point72 Hong Kong's SLNO Position: Q4 2020 in Review

Point72 Hong Kong sold out of Soleno Therapeutics (SLNO) in Q4 2020, closing a stake of 24 shares — an estimated $1K sold.

Point72 Hong Kong first reported a position in SLNO in Q2 2020 and held it in 2 quarters. The position peaked at $1K in Q3 2020. 67 funds tracked by Wall St. Rank hold SLNO as of Q4 2020.

  • Point72 Hong Kong reported no remaining Soleno Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Point72 Hong Kong sold 24 Soleno Therapeutics shares in Q4 2020, an estimated $1K.
  • Point72 Hong Kong first reported a position in Soleno Therapeutics in Q2 2020 and held it in 2 quarters.
  • Point72 Hong Kong's Soleno Therapeutics position peaked at $1K in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2020.

Based on Point72 Hong Kong's 13F filing for Q4 2020, filed 16 Feb 2021.